Tumor features that have been associated with a good clinical response to anti-PD-1/PD-L1 checkpoint blockade therapies include T-cell infiltration, PD-L1 expression in tumor and/or immune cells, increased tumor mutational burden (TMB), and interferon gamma (IFNγ)-derived T-cell gene expression profiles [5]. This evidence concerns the gene CD274 and neoplasm.